The Effectiveness of a Computer Reminder System for Laboratory Monitoring of Metabolic Syndrome in Schizophrenic Outpatients Using Second-generation Antipsychotics

Abstract

Introduction: A computer reminder system (CRS) may help psychiatrists follow guidelines and monitor patients at risk of metabolic syndrome. This study explores the effectiveness of a CRS for outpatients with schizophrenia.

Methods: The study data were collected from July 2004 to July 2008. A CRS was implemented in July 2006. The intervention group was patients taking either clozapine, olanzapine, risperidone, or quetiapine with a CRS. The control group was patients taking either sulpiride or zotepine without a CRS. We defined a qualified patient visit (QPV) as a visit in which metabolic monitoring adhered to established guidelines when the patient visit was within 6 months of performing the recommended laboratory examinations. We compared the percentage difference in QPVs between the 2 study groups.

Results: The percentage of QPVs in the intervention group was significantly higher than the control group (OR=3.51, 95% CI=1.83~6.73, P=0.0002) after adjusting potential confounding factors. The intervention group was divided into a high metabolic risk (clozapine and olanzapine) subgroup and an intermediate metabolic risk (risperidone and quetiapine) subgroup and compared with the control group. The percentage of QPVs in the high risk subgroup was significantly higher than the intermediate risk subgroup (OR=4.27, 95% CI=2.71~6.75, p<0.0001) and control group (OR=6.99, 95% CI=3.48~14.07, p<0.0001).

Discussion: The percentage of QPVs in the intervention group was higher than the control group and the different metabolic risk of SGAs also influenced the performance of laboratory examinations. Further studies are needed to confirm the results of our studies.

Key words

metabolic syndrome - computer reminder system - schizophrenia - antipsychotics

• References

• 1 Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62 (Suppl. 27) 15-26
• 2 Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001; 62 (Suppl. 23) 30-38
• 3 Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?. CNS Drugs 2002; 16: 77-89
• 4 Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001; 11: 25-32
• 5 Bou Khalil R. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-euro-american societies. Clin Neuropharmacol 2012; 35: 141-147
• 6 Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004; 24 (Suppl. 01) 7-14
• 7 Morrato EH, Cuffel B, Newcomer JW et al. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. J Clin Psychopharmacol 2009; 29: 26-32
• 8 Expert G. ‘Schizophrenia and Diabetes 2003’ Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry 2004; 184: 112-114
• 9 De Nayer A, De Hert M, Scheen A et al. Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics. Encephale 2007; 33: 197-202
• 10 Mitchell AJ, Delaffon V, Vancampfort D et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012; 42: 125-147
• 11 Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68 (Suppl. 01) 20-27
• 12 Harris MI, Eastman RC, Cowie CC et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999; 22: 403-408
• 13 Ziemer DC, Doyle JP, Barnes CS et al. An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving Primary Care of African Americans with Diabetes (IPCAAD) 8. Arch Intern Med 2006; 166: 507-513
• 14 Mohan AV, Phillips LS. Clinical inertia and uncertainty in medicine. JAMA 2011; 306: 383
• 15 Phillips LS, Branch WT, Cook CB et al. Clinical inertia. Ann Intern Med 2001; 135: 825-834
• 16 Martens JD, van der Aa A, Panis B et al. Design and evaluation of a computer reminder system to improve prescribing behaviour of GPs. Stud Health Tech Informat 2006; 124: 617-623
• 17 McDonald CJ, Hui SL, Smith DM et al. Reminders to physicians from an introspective computer medical record. A two-year randomized trial. Ann Intern Med 1984; 100: 130-138
• 18 Wilbur L, Huffman G, Lofton S et al. The use of a computer reminder system in an emergency department universal HIV screening program. Ann Emerg Med 2011; 58 (Suppl. 01) 71-73
• 19 Nilasena DS, Lincoln MJ. A computer-generated reminder system improves physician compliance with diabetes preventive care guidelines. Proc Annu Symp Comput Appl Med Care 1995; 640-645
• 20 Agostini JV, Zhang Y, Inouye SK. Use of a computer-based reminder to improve sedative-hypnotic prescribing in older hospitalized patients. J Am Geriatr Soc 2007; 55: 43-48
• 21 Del Monte MT, Bostwick JR, Bess JD et al. Evaluation of a computer-based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second-generation antipsychotics. J Clin Pharm Ther 2012; 37: 668-673
• 22 Baptista T, Molina MG, Martinez JL et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation. Pharmacopsychiatry 1997; 30: 256-262
• 23 Baptista T, Alastre T, Contreras Q et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation. Pharmacopsychiatry 1997; 30: 250-255
• 24 Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl. 01) 1-93
• 25 Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62 (Suppl. 27) 15-26 discussion 40–41
• 26 Wetterling T, Mussigbrodt HE. Weight gain: side effect of atypical neuroleptics?. J Clin Psychopharmacol 1999; 19: 316-321
• 27 Wu RR, Zhao JP, Liu ZN et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006; 186: 572-578
• 28 Huang MC, Lu ML, Tsai CJ et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 2009; 120: 274-280
• 29 Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-962
• 30 Bungard TJ, Ghali WA, Teo KK et al. Why do patients with atrial fibrillation not receive warfarin?. Arch Intern Med 2000; 160: 41-46
• 31 Ziemer DC, Doyle JP, Barnes CS et al. An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving Primary Care of African Americans with Diabetes (IPCAAD) 8. Arch Intern Med 2006; 166: 507-513
• 32 Phillips LS, Ziemer DC, Doyle JP et al. An endocrinologist-supported intervention aimed at providers improves diabetes management in a primary care site: improving primary care of African Americans with diabetes (IPCAAD) 7. Diabetes Care 2005; 28: 2352-2360
• 33 Perlin JB, Pogach LM. Improving the outcomes of metabolic conditions: managing momentum to overcome clinical inertia. Ann Intern Med 2006; 144: 525-527